Report of Foreign Issuer (6-k)
June 19 2017 - 11:12AM
Edgar (US Regulatory)
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form
6-K
REPORT OF
FOREIGN PRIVATE ISSUER
PURSUANT TO RULE
13A-16
OR
15D-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
June 2017
Commission
File Number
1-15182
DR.
REDDYS LABORATORIES LIMITED
(Translation of registrants name into English)
8-2-337,
Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form
20-F
or Form
40-F.
Form 20-F ☒ Form
40-F ☐
Indicate by check mark if the registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(1): ☐
Note:
Regulation
S-T
Rule 101(b)(1) only permits the submission in paper of a Form
6-K
if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the
registrant is submitting the Form
6-K
in paper as permitted by Regulation
S-T
Rule 101(b)(7): ☐
Note:
Regulation
S-T
Rule 101(b)(7) only permits the submission in paper of a Form
6-K
if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or
legally organized (the registrants home country), or under the rules of the home country exchange on which the registrants securities are traded, as long as the report or other document is not a press release, is not required
to be and has not been distributed to the registrants security holders, and, if discussing a material event, has already been the subject of a Form
6-K
submission or other Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule
12g3-2(b)
under the Securities Exchange Act of 1934.
Yes ☐ No ☒
If Yes is marked, indicate below the file number assigned to registrant in connection with Rule
12g3-2(b):
82- .
EXHIBITS
|
|
|
Exhibit
Number
|
|
Description of Exhibits
|
|
|
99.1
|
|
Notice to Stock Exchanges re: Clarification on news item appearing in Business Standard dated June 14, 2017 captioned Dr Reddys recalls 3.25L cartons Cipla-made acne drug from US., dated June 15,
2017.
|
|
|
99.2
|
|
Notice to Stock Exchanges re: Audit of Formulations manufacturing plant at Srikakulam, Andhra Pradesh by the U.S. FDA, dated June 16, 2017.
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
DR. REDDYS LABORATORIES LIMITED
(Registrant)
|
|
|
|
|
Date: June 19, 2017
|
|
|
|
By:
|
|
/s/ Sandeep Poddar
|
|
|
|
|
Name:
|
|
Sandeep Poddar
|
|
|
|
|
Title:
|
|
Company Secretary
|
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Mar 2024 to Apr 2024
Dr Reddys Laboratories (NYSE:RDY)
Historical Stock Chart
From Apr 2023 to Apr 2024